Ashvattha Therapeutics, Inc
2:15 PM - 2:30 PM (EST), Monday, February 6, 2023 ・ Palace
Clinical-stage biopharmaceutical
company focused on developing novel hydroxyl
dendrimer therapeutics (HDTs) to treat unmet
medical needs in neurology, ophthalmology,
inflammatory diseases and oncology.
Three clinical stage programs are ongoing with data readouts in 2023.
company focused on developing novel hydroxyl
dendrimer therapeutics (HDTs) to treat unmet
medical needs in neurology, ophthalmology,
inflammatory diseases and oncology.
Three clinical stage programs are ongoing with data readouts in 2023.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Ophthalmology
Lead Product in Development:
D-4517.2
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
